Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 242

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions

Open access
Miller, Julie J, Gonzalez Castro, L Nicolas, McBrayer, Samuel, Weller, Michael, Cloughesy, Timothy, Portnow, Jana, Andronesi, Ovidiu, Barnholtz-Sloan, Jill S, Baumert, Brigitta G, Berger, Mitchell S, Bi, Wenya Linda, Bindra, Ranjit, Cahill, Daniel P, Chang, Susan M, Costello, Joseph F, Horbinski, Craig, Huang, Raymond Y, Jenkins, Robert B, Ligon, Keith L, Mellinghoff, Ingo K, Nabors, L Burt, Platten, Michael, Reardon, David A, Shi, Diana D, Schiff, David, Wick, Wolfgang, Yan, Hai, von Deimling, Andreas, van den Bent, Martin, Kaelin, William G, Wen, Patrick Y · 2023 · Neuro-Oncology

Abstract

Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant primary brain tumors diagnosed in patients younger than 50, constituting an important cause of morbidity and mortality. In recent years, there has been significant progress in understanding the molecular pathogenesis and biology of these tumors, sparking multiple efforts to improve their diagnosis and treatment. In this consensus review from the Society for Neuro-Oncology (SNO), the current diagnosis and management of IDH-mutant gliomas will be discussed. In addition, novel therapies, such as targeted molecular therapies and immunotherapies, will be reviewed. Current challenges and future directions for research will be discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/noac207

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 242

Metadata

Authors
Miller, J. J., Gonzalez Castro, L. N., McBrayer, S., Weller, M., Cloughesy, T., Portnow, J., Andronesi, O., Barnholtz-Sloan, J. S., Baumert, B. G., Berger, M. S., Bi, W. L., Bindra, R., Cahill, D. P., Chang, S. M., Costello, J. F., Horbinski, C., Huang, R. Y., Jenkins, R. B., Ligon, K. L., Mellinghoff, I. K., Nabors, L. B., Platten, M., Reardon, D. A., Shi, D. D., Schiff, D., Wick, W., Yan, H., von Deimling, A., van den Bent, M., Kaelin, W. G., & Wen, P. Y.
Venue
Neuro-Oncology
Published
2022-10-12
Volume
25
Issue
1
Pages
4-25
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W4306247069
Cited by
242
References
30
FWCI
24.41
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. https://app.cochat.ai/papers/10.1093/neuonc/noac207
The paper
Miller, J. J., Gonzalez Castro, L. N., McBrayer, S., Weller, M., Cloughesy, T., Portnow, J., Andronesi, O., Barnholtz-Sloan, J. S., Baumert, B. G., Berger, M. S., Bi, W. L., Bindra, R., Cahill, D. P., Chang, S. M., Costello, J. F., Horbinski, C., Huang, R. Y., Jenkins, R. B., Ligon, K. L., . . . Wen, P. Y. (2023). Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro-Oncology. https://doi.org/10.1093/neuonc/noac207

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.